|
|
STROPHANTHIN G
STROPHANTHIN K
-
| StockNo |
Product description |
Status |
| EB0280-424-20 |
STROPHANTIN
G AMPOULE 0.25 MG/1 ML (0.025%) |
 |
| EB0280-424-36 |
STROPHANTIN
K AMPOULE 025 MG/1 ML (0.025%) |
|
-
- COMPOSITION:
Strophanthin G 0.25 mg/1 ml in one ampoule
Strophanthin K 0.25 mg/1 ml in one ampoule
ACTION:
Cardiac glucoside with cardiotonic action: enhances systolic
contractions, while reducing their duration; slows down the
cardiac rhythm and prolongs the diastole which improves the
blood flow to the ventricles; it slightly reduces the
excitability of the cardiac conduction system; increases
diuresis which is associated mainly with the general improvement
of blood circulation. It has a highly effective, fast and
short-term action. After intravenous administration the effect
is manifested 5-10 min later, reaching its maximum after 1-1 1/2
h. It does not cumulate. The cardiotonic effect of strophanthin
G and its toxic action are almost 1.5 times stronger than those
of strophanthin K.
INDICATIONS:
Acute cardiovascular insufficiency, left venticular
insufficiency predominantly (cardiac asthma, pulmonary edema,
acute myocardial infarction); severe form of chronic cardiac
insufficiency; acute infectious diseases; paroxymal tachycardia.
CONTRAINDICATIONS:
Pronounced, grave organic changes in the heart and vessels, acute
myocarditis and endocarditis, tendency to thromboembolic processes,
bigeminy, advanced cases of cardiosclerosis, grave renal
insufficiency.
SIDE EFFECTS:
In overdosage (abrupt bradycardia, extrasystoles, bigemiy) - the
treatment is discontinued or the doses are reduced and the interval
between the individual injections is prolonged.
PRECAUTIONS:
After treatment with digitalis drugs, due to their cumulation,
injection of strophanthin should start after an interval of several
days and with a reduced first dose. |
DRUG INTERCATIONS:
Cardiac glucosides interact with an extremely large number of drugs.
Some of the more important interactions are: strophanthin toxicity
is enhanced bymagnesium sulfate, all 'bitter' salts, amphotericin,
biz acodal, carbenoxolon, ACTH, mineral oils, glucocorticoids,
insulin, laxative saluretic agents; strophanthin action is enhanced
by acetazolamide, quinidine, dehydrocholic acid, diasoxide,
diclophenamine, himecromon; its action is diminished by coumarin
anticoagulants, thyroxine, potassium agents, potassium retaining
diuretics, etc.
DOSAGE AND ADMINISTRATION:
Strophanthin G
It is intravenously administered in a single mean daily dose of 0.25
mg, diluted with 10 ml physiologic salt solution or 10-20 % glucose
solution, injected very slowly (within 2-3 min). the first
injections are with a lower dose, cautiously - for testing the
individual sensitivity to the drug (particularly after digitalis
treatment) the duration of the treatment course is determined by the
therapeutic response and by the indications for treatment of the
concrete patient.
Strophanthin K
It is intravenously injected in a single daily dose of 0.25-0.5 mg,
diluted with 10-20 ml 10-20 % glucose solution or physiologic salt
solution in the same quantity. When intravenous injection is
impossible, intramuscular injections can be prescribed in a dose
increased about 1.5 times. In case of painful site of injection, it
can be infiltrated with 5 ml of 2 % novocain solution (Caution:
hypersensitivity to novocain).
MEDICINAL FORM AND PACKAGE:
Strophanthin G
Packages with 10 and 50 ampoules of 0.25 mg/ 1 ml (0.025 %).
Strophanthin K
Packages with 10 and 50 ampoules of 0.25 mg/1 ml (0.025 %).
STORAGE:
At moderate temperature (15-30° C).
EXPIRY:
2 (two) years.
|
|
|
